Supporting you at every stage
Growing a tiny human can be exhausting, but your glucose management doesn’t need to be!
Dexcom ONE+ is our most accurate Continuous Glucose Monitoring (CGM) system*,1 giving you the confidence to make informed treatment decisions.
Dexcom CGM is approved for people living with type 1, type 2 and gestational diabetes for ages 2 years and over.
The Australian Government offers access to subsidised Dexcom G7 or Dexcom G6 CGM systems for Australians living with type 1 diabetes through the National Diabetes Services Scheme (NDSS) Initiative.†
What is Continuous Glucose Monitoring (CGM)?
Continuous Glucose Monitoring (CGM) is a tool that measures glucose levels 24/7 using a sensor under the skin. The Dexcom ONE+ system includes a one-touch sensor applicator and a mobile app‡ that shows real-time and past glucose data. It wirelessly sends readings to devices like smartphones, smartwatches, or an optional receiver.‡ This system provides real-time glucose readings with zero fingerpricks§ and can alert you if your glucose levels are too high or too low.
Display devices sold separately.‡
Easy. Accurate.* Better Health Outcomes.1-5
Dexcom CGM is approved for people living with type 1, type 2 and gestational diabetes for ages 2 years and over.
Easy to use
Easy self-start CGM which seamlessly integrates into your daily routine.
Superior accuracy*,1
Dexcom ONE+, alongside Dexcom G7, are our most accurate CGM systems*,1 giving you the confidence to make informed treatment decisions.
Better health outcomes1-5
Dexcom CGMs are shown to improve quality of life, reduce highs and lows, lower A1C and improve time in range.1-7
Zero fingerpricks§
Dexcom CGM requires zero fingerpicks.§
Take control of your glucose management
Maintaining tight gylcaemic management is important when you're expecting, but hormonal changes can make this challenging.
Let Dexcom assist you in taking care of your glucose management so you can focus on what's important to you.
Speak to your healthcare team about accessing the Dexcom CGM system - NDSS funding for Dexcom G7 or Dexcom G6 CGM systems are available for women living with type 1 diabetes.† If you don’t quality for the NDSS subsidy, visit our online shop by clicking on the button below.
Ready to take the next step?
Eligible for CGM Subsidy?
The Australian Government offers access to subsidised Continuous Glucose Monitoring (CGM) for Australians living
with type 1 diabetes through the
National Diabetes Services Scheme
(NDSS) Initiative.§
Not eligible for subsidy?
You can easily shop via AMSL Diabetes (a Dexcom company) our online store by clicking the button below!
Still have questions about Dexcom G7?
Speak to one of our product specialists.
These studies did not include pregnant women.
§ If your glucose alerts and readings from the Dexcom ONE+ do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* Dexcom G7 and ONE+ are our most accurate CGM systems as compared to Dexcom G6
† Eligibility criteria applies. Visit ndss.com.au/cgm for more details
‡ Display devices sold separately. To view a list of compatible smart devices, please visit www.dexcom.com/compatibility. A receiver can be acquired as an optional display device
|| These products are indicated for persons with diabetes mellitus age 2 years and older where SMBG is indicated
* Dexcom G7 and ONE+ are our most accurate CGM systems as compared to Dexcom G6
† Eligibility criteria applies. Visit ndss.com.au/cgm for more details
‡ Display devices sold separately. To view a list of compatible smart devices, please visit www.dexcom.com/compatibility. A receiver can be acquired as an optional display device
|| These products are indicated for persons with diabetes mellitus age 2 years and older where SMBG is indicated
References: 1 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 2 Beck RW, et al. JAMA. 2017;317(4):371-378. 3 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 4 Martens T, et al. JAMA. 2021;325(22):2262-2272. 5 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 6 Polsky S, et al. Diabetes Technol Ther. 2024;26(5):307-12. 7 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202. 8 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39.